Approximately half of Ph-like B-ALL patients have CRLF2 (cytokine receptor-like factor 2) overexpression, with or without accompanying mutations in JAK2 tyrosine kinase, and are candidates for treatment with JAK inhibitors [6, 7]. Here, CRLF2 is linked to acute lymphoblastic leukemia.